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Myocarditis contributes to the global burden of cardiovascular disease primarily through sudden death and
dilated cardiomyopathy. A systematic approach to identify the cardiovascular mortality and major
morbidity attributable to myocarditis has not been performed. A writing group convened by the GBD
2010 (Global Burden of Diseases, Injuries and Risk Factors) Study systematically reviewed the world’s
literature by a manual review of all titles since 1966 on myocarditis identiﬁed using Ovid Medline,
development of a disease model, and provision of estimates when possible of the incidence, prevalence,
risk of death, and major morbidity for the world regions. Accurate population-based estimates of
myocarditis incidence and prevalence are not directly available in any world region. However, a model that
quantitates the risk of acute death and chronic heart failure following myocarditis was derived from the
published data. Using hospital dismissal data, the burden of myocarditis as a percentage of prevalent heart
failure varied by age and region from approximately 0.5% to 4.0%. The novel combination of multiple
data sources may provide an estimate of the years of life lost and years of life disabled from myocarditis.
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CC BY-NC-ND license.The GBD 2010 (Global Burden of Diseases, Injuries
and Risk Factors) writing group on myocarditis was
charged with the task of identifying when possible the
global incidence, prevalence, morbidity, and mortality of
myocarditis. The project goals included stratifying the
available data into 21 world regions by age, sex, and in-
come level. The original scope included pericarditis and
endocarditis as well as myocarditis. Early in the writing
process a section of the original writing group separated to
investigate the global burden of endocarditis. A review of
the world’s literature on idiopathic pericarditis and myo-
pericarditis revealed a low rate of sudden death and
chronic heart failure [1,2]. Thus, idiopathic pericarditis
and myopericarditis were excluded from the disease model
development and subsequent morbidity and mortality
calculations. Other writing groups that focused on the
burden of tuberculosis and HIV addressed pericarditis as a
consequence of these speciﬁc disorders.
Although the causes of myocarditis are diverse and
vary regionally, the GBD myocarditis writing group pri-
marily described the impact of idiopathic, viral, and post-
viral autoimmune myocarditis. Other writing groups that
focused on Chagas disease, rheumatic heart disease, and
HIV included heart failure from cardiomyopathy in their
estimates of disease burden (Fig. 1). Thus, this report from
the GBD writing group on myocarditis should be read in
combination with the other GBD reports to gather aGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 121-129comprehensive picture of the global burden of inﬂamma-
tory cardiovascular disease.METHODS
An Ovid Medline search to January 2009 using the terms
“myocarditis.mp. or exp myocarditis” and “pericarditis.mp.
or exp Pericarditis” was performed. Case reports and re-
ports without human subjects were excluded based on a
manual review of all abstracts and titles. Only case series
and clinical trials that included clinical outcomes of heart
failure and death were held for further review. Additional
studies were identiﬁed from the authors’ personal manu-
script ﬁles. The results of this effort are illustrated in
Figure 2. Myocarditis cases in hospital dismissal databases
were identiﬁed using International Classiﬁcation of Disease
10 (ICD-10) codes I40 (acute myocarditis) and I42
(myocarditis in diseases classiﬁed elsewhere).
The writing group met by teleconferences and several
face-to-face meetings and communicated extensively to
develop a myocarditis disease model that captured major
disease features. By necessity, the model is a simpliﬁcation
of the actual disease process, intended to allow the com-
bination of data from other writing groups by the GBD core
analysts for an integrated calculation of years of life lost and
years of life disabled. Several aspects of myocarditis inﬂu-
enced the development of the model. First, the clinicalj.gheart.2014.01.007
121
FIGURE 1. Major and detailed causes of heart failure used in the 2010 GBD
project. Myocarditis was combined with cardiomyopathy in the detailed cause
analysis and with 11 disorders in the “other” major cause grouping. CHF,
congestive heart failure; DCM, dilated cardiomyopathy; GBD, Global Burden of
Diseases, Injuries and Risk Factors. Reproduced with permission from: Vos T,
Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae
of 289 diseases and injuries 1990-2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet 2013;380:2163–96 [5].
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the syndrome of heart failure, anginal-type chest pain, and
occasionally sudden death from ventricular arrhythmias. The
outcome of myocarditis is well known to vary with etiology
and age, but the major long-term sequelae for all causes is
chronic heart failure, generally associated with dilated car-
diomyopathy [3]. Therefore, the writing committee evaluatedall studies of myocarditis regardless of presenting clinical
syndrome. Occasionally chronic chest pain following
myocarditis can also be disabling; however, chronic symp-
tomatic heart failure from myocarditis is the only long-term
cause of morbidity in the disease model (Fig. 3).
The deﬁnition of myocarditis used in published studies
varies widely. Many authorities recommend histological or
immunohistological criteria that require endomyocardial
biopsy (EMB), surgical heart specimens, or autopsy [4]
When possible, the committee used data from histologi-
cally conﬁrmed registries and clinical trials to estimate the
risks of death and chronic heart failure. However, much of
the published literature and nearly all cases of myocarditis
based on hospital dismissal diagnosis codes were not
linked to a speciﬁc pathological diagnosis. The writing
committee decided to review all of the available data,
regardless of diagnostic criteria used, recognizing that
myocarditis, as used in the ﬁnal report, refers to a heter-
ogenous group of diseases with variable clinical and
pathological features. As a consequence, there is an
imperfect distinction between myocarditis and acute
dilated cardiomyopathy, and the disease burden from the
myocarditis and cardiomyopathy cohorts are usually re-
ported together in the 2010 GBD tables and ﬁgures [5,6].RESULTS
The major ﬁndings of the literature review are summarized
below. Because of space limitations, this report cites mainly
representative examples of the most important primary
sources with the intent to convey the relevant epidemio-
logical data on myocarditis by world region.Asia
A review of the case series from Asia between 1966 to the
mid 2000s revealed speciﬁc regional causes such as diph-
theria (Afghanistan and India) [7], typhoid fever [8],
rubella, scorpion bite (India), and a variety of virus in-
fections including coxsackievirus B (CVB) [9] and chi-
kungunya [10]. Hepatitis C virus seemed to be an
important cause of myocarditis in Japan [11]. The data
from these case series suggested temporal and regional
variation in etiology but did not permit more than a
qualitative analysis of myocarditis causes.
In Japan, the rate of myocarditis was estimated from an
unselected national registry of 377,841 autopsies; 434 of
these patients (0.11% or about 1:1000) had idiopathic,
interstitial, viral, or nonspeciﬁc myocarditis [12]. In
contrast, the rate of myocarditis was 3% (6 of 200) in
autopsies of patients experiencing sudden death in Japan
[13]. Of 97 (77 male, 20 female) school children who
experienced sudden death in Kanagawa prefecture, 3 of the
18 (16.6%) with histologically established cardiovascular
disease had myocarditis [14]. However, the majority—60
of the 97 children—had acute heart failure of unknown
etiology, suggesting a need for a sensitive and speciﬁcGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 121-129
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noninvasive diagnostic test to identify myocarditis as a
cause of acute cardiomyopathy.
One clinical series of 20 patients from Japan with acute
myocarditis and heart failure was followed for 49 months.
Two patients (10%) died, 5 (25%) developed chronic
dilated cardiomyopathy (DCM), and 10 (50%) recovered
without arrhythmias [15]. Acute myocarditis with severe
heart failure was associated with the 2009 inﬂuenza
pandemic A (H1N1) in Japan. In a national survey on
myocarditis associated with the 2009 pandemic, 15 pa-
tients were reported, 10 of whom had fulminant myocar-
ditis (6 proven by biopsy). All 10 patients required
mechanical circulatory support (intra-aortic balloon
pumping and/or percutaneous cardiopulmonary support),
and remarkably 8 survived. These ﬁndings support ob-
servations in other world regions that patients with
fulminant myocarditis can frequently recover when
managed with appropriate mechanical circulatory
support [16].
These data suggest that acute myocarditis is an
important cause of sudden death and chronic DCM in
Japan and likely the rest of the Asian region. Fulminant
myocarditis after a severe viral illness is uncommon but can
resolve with management that includes timely hemody-
namic support. There are substantial gaps in the outcome
data for almost all countries and age groups. A strategy to
ﬁll these gaps may include the use of national clinical and
death registries to identify cases coupled with precise
diagnostic tools to validate the case identiﬁcation.FIGURE 2. Literature search strategy for myocarditis.Australasia
The literature from Australia and New Zealand described
regional variations in etiologies and important contribu-
tions to the natural history of histologically conﬁrmed
myocarditis in children. Reports from this region included
associations of myocarditis with CVB and enterovirus 71
viral epidemics [17,18], toxic myocarditis from clozapine
and anabolic steroid use [19], and rarely myocarditis
associated with smallpox vaccination. The reports
regarding clozapine noted an incidence of 0.7% to 1.2%,
with most patients presenting within 3 weeks from drug
initiation [20]. The estimated rate of death was 10%, with
recovery in about half of the patients and 15% with
persistent left ventricular (LV) dysfunction [21]. Follow-up
data were not available for about 25% of patients.
Several important contributions from the autopsy
literature characterize the role of myocarditis in sudden
death. In one series from Sydney of 193 patients younger
than 35 years experiencing sudden death, 12% (39) were
due to myocarditis [22]. A second autopsy series from
eastern Sydney of patients aged 5 to 35 years reported
myocarditis as a cause of sudden death in 11.6% of 241
nontraumatic cardiac cases [23]. In a slightly older series of
841 patients (aged 16 to 39 years) with out-of-hospital
cardiac arrests from Melbourne, 3.5% were due to
myocarditis [24]. An autopsy series from AdelaideGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 121-129Children’s Hospital described the spectrum of presentation
in 32 conﬁrmed myocarditis cases (in 16 of 32, myocarditis
was the only cause of death; the remaining 16 were also
associated with other severe diseases). Sudden death was
the presentation of the disease in 5 of 15 children with
myocarditis as the sole cause of death. In 3 of these 5,
sudden death was not preceded by symptoms [25].
The National Australian Childhood Cardiomyopathy
Study included all children with primary cardiomyopathy
who presented between January 1, 1987, and December 31,
1996, and who were younger than 10 years of age at pre-
sentation. A series of reports from this national registry
helped characterize the natural history of conﬁrmed and
suspectedmyocarditis in children. Lymphocyticmyocarditis
was present in 25 of 70 children with DCM who underwent
cardiac histologic examination (35.7 percent), and in 25 of
62 children who underwent histological examination within
2 months after presentation (40.3%) [26].
Despite a high initial mortality, patients with lym-
phocytic myocarditis diagnosed during life had a better
survival than those with nonspeciﬁc histological ﬁndings
[27]. Survival and outcome for children with lymphocytic
myocarditis in a previous Australian study was also better
than for those with nonspeciﬁc histology [28]. Although
the clinical status of long-term survivors of lymphocytic
myocarditis is good, the severity of acute myocarditis is123
FIGURE 3. Disease model of myocarditis.
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124substantial. Of all children with lymphocytic inﬁltrates,
50% died during the ﬁrst days of hospitalization or pre-
sented with sudden death.
In summary, the data from the National Australian
Childhood Cardiomyopathy Study and other autopsy data
are similar to those reported from Japan and support the
conclusion that myocarditis is an important cause of acute
cardiovascular death in this region. The clinical outcomes
data from the National Australian Childhood Cardiomyop-
athy Study provided one of 2 sets of national outcomes for
myocarditis in children (the other being the North American
Pediatric Cardiomyopathy registry). Similar long-term
outcome data were lacking for adults with myocarditis in
this region. The substantial contribution of the National
Australian Childhood Cardiomyopathy Study to our un-
derstanding of the global burden ofmyocarditis suggests that
similar strategies in the adult population may help to inform
public policy and health resource management.
Mexico and Central and South America
The publications from this region either dealt with the
incidence of myocarditis in the general population or
addressed practical clinicopathological issues including the
diagnostic value of EMB in distinguishing myocarditis from
DCM, the evolution of myocarditis into DCM, and the
association of myocarditis with serological viral diagnosis.
The regional literature described features of special etiol-
ogies like measles, meningococcal meningitis, AIDS,
dengue fever, diphtheria and Kawasaki diseaseerelated
myocarditis. As noted previously, Chagas disease was
excluded from this regional literature survey.
At a tertiary institution in Mexico during a 10-year
period (1992 to 2003), acute myocarditis was diagnosedin 49 adult patients, 17 women and 32 men, with a median
age of 24 and 28 years, respectively [29]. Patients with
myocarditis represented 1 of 1,000 patients per year
(0.1%), all of whom had positive serology for CVB or
echovirus. Twenty-nine patients (61%) developed chronic
DCM, and 3 patients (6%) died in the acute phase of the
disease. Similarly, CVB serotypes B2 and B4 and echovirus
serotype 1 were identiﬁed in the Brazilian Amazon region
in a pediatric series of 15 patients (age 0 to 10 years) with
myocarditis or DCM [30]. The diagnosis was made by
evaluation of stool specimens, throat swabs, and when
possible serum anti-CVB antibody titers.
The prevalence of histologically diagnosed myocarditis
in DCM ranged from 13% in a study of 15 patients from
Mexico [31] to 65% in a study of 23 patients from Chile
[32]. Most patients with inﬂammatory inﬁltrates had a
clinical history of less than 6 months’ duration, and 57% of
the 23 patients from Chile [32] were diagnosed less than 3
months before the EMB. Although these cohorts are small,
the regional prevalence of myocarditis in acute DCM was
similar to the rates reported from Australia, Europe, and
North America.
Special etiologies. During a 14-year period, 176 pa-
tients with measles were hospitalized at Hospital Infantil de
Mexico and 23 (13%) died. Myocarditis was a rare
complication of measles. Medical complications (including
myocarditis) and mortality were more likely to occur in
very young nonimmunized, malnourished children.
In a report from Brazil [33], the prevalence of
myocarditis among children with fatal meningococcal
meningitis was 42% (13 of 31 children, age 47.6  39.8
months) but was minimal in 11 of the 13 (85%). Therefore,GLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 121-129
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a clear contribution of myocarditis and myocardial
dysfunction to fatal outcome in meningococcal infection
was not proven. The prevalence of myocarditis was 13% in
a report from Colombia of 105 children with either dengue
fever (12%) or dengue hemorrhagic fever (88%) [34].
In an autopsy series of 51 patients with AIDS from
Mexico, myocarditis, pericarditis, and endocarditis were
each found in 10% to 12% of cases [35]. Cardiovascular
pathology, including coronary disease, pericardial effusion,
and DCM, was diagnosed during life in 12% and
remarkably in 43% at autopsy. Therefore, the authors
recommend screening for cardiovascular disease with
electrocardiography and echocardiography in patients with
AIDS.
The clinical features and outcome of acute diphtheric
myocarditis were described in 2 reports from Colombia
[36] and Chile [37]. In the later report, 24 of 46 patients
(52%) admitted with diphtheric myocarditis had bradyar-
rhythmias and 11 (17%) died. All 7 patients with third-
degree atrioventricular block, a patient with bifascicular
block, and 3 of the 6 patients with bundle branch block
died. Seven died of cardiogenic shock and 4 of ventricular
ﬁbrillation. Conduction system disturbances in patients
with diphtherial myocarditis were markers of severe
myocardial damage and a poor prognosis. In addition,
ventricular pacing did not improve survival.
The incidence of myocarditis ranged from 5% to 46%
in 3 series of pediatric patients with Kawasaki disease
[38e40]. Kawasaki disease mainly affected children age 1
to 4 years, evolved with fever and vasculitis in diverse
organs, and in the heart mainly affected the coronary ar-
teries. The male to female ratio ranged from 3.3:1 to 9:1.
Gamma globulin treatment combined with aspirin effec-
tively controlled the disease process [40]. Death was related
to coronary complications, not to myocarditis.
Taken together with observations fromWestern Europe
and North America, the Mexican data suggested that be-
tween 10% and 50% of cases of acute DCM are likely due to
myocarditis. Reasons for the heterogeneity in observed rates
should be explored systematically. In addition, the causes of
myocarditis in Mexico and Central and South America
differed from those in developed nations in Asia, Western
Europe, and North America, which suggests a need for
region-speciﬁc screening and diagnostic strategies.
Africa and the Middle East
The published data on myocarditis in Africa revealed a
regional and possibly temporal variation in causes that
include viruses (particularly HIV) [41], peripartum car-
diomyopathy, and occasionally infections such as
trypanosomiasis [42] and shigelloses. As was the case in
Asian myocarditis literature, the data did not permit an
estimate of the relative contributions of speciﬁc etiologies
to the burden of myocarditis.
The rate of myocarditis as a percent of heart failure
varied by region and possibly by etiology. A study of 76GLOBAL HEART, VOL. 9, NO. 1, 2014
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revealed that none had myocarditis and suggested that
conditions other than myocarditis should be considered as
causes of DCM [43]. A second study of LV EMB specimens
from 18 African patients (14 men) with idiopathic DCM in
Nairobi revealed that 9 patients (50%) had evidence of
healing myocarditis [44]. In a study of 11 African women
from Nairobi who presented with the clinical features of
peripartum cardiomyopathy and who had EMB, 5 patients
had evidence of a “healing myocarditis.” Of the 9 patients
who were followed up, 3 of 4 with myocarditis had
persistent heart failure and 4 of 5 without myocarditis
improved.
Although there are several large African cardiovascular
disease registries, most cases are characterized only by
clinical and echocardiographic criteria. Few studies utilize
heart biopsy or cardiac magnetic resonance imaging (MRI).
For example, a report of 1,507 patients referred for echo-
cardiographic evaluation in Harare, Zimbabwe, revealed
1,153 (76.5%) abnormal studies. The major diagnoses
were rheumatic heart disease, pericardial disease, DCM,
hypertensive heart disease, and peripartum cardiomyopa-
thy. Only 34 of 1,153 cases were attributed to acute
myocarditis [45]. In a registry of 572 consecutive patients
with heart failure referred to the National Cardiothoracic
Centre in Accra, Ghana, the main causes of heart failure
were hypertension (21.3%), rheumatic heart disease
(20.1%), and cardiomyopathy (16.8%). Myocarditis was
not identiﬁed as a separate cause.
In a similar example, 167 patients (99 men and 68
women) presenting with clinical and echocardiographic
signs of heart failure were reported from Yaounde General
Hospital, Cameroon. The main etiologies were hyperten-
sion (54%), cardiomyopathies (26%), and valvular heart
diseases (25%) [46].
The largest such heart disease registry is the Heart of
Soweto Study, which characterized the heart disease burden
in an urban African community. From January 1 to Dec 31,
2006, 4,162 patients with conﬁrmed cardiovascular disease
were evaluated at the cardiology unit at the Chris Hani
Baragwanath Hospital in Soweto, South Africa. Although
heart failure was the most common primary diagnosis,
myocarditis was not evaluated as a separate diagnostic
category [47].
A recent summary of the current state of knowledge on
the epidemiology and etiology of cardiomyopathy in peo-
ple living in Africa identiﬁed DCM as a major cause of heart
failure throughout Africa [48]. Myocarditis as a separate
entity was rarely identiﬁed due to a lack of readily available
diagnostic tools. The authors noted marked regional vari-
ation in the pathogenesis of DCM, suggesting a heteroge-
neity of causative factors. In summary, the data regarding
myocarditis in Africa were limited by a lack of available
accurate diagnostic tools. Efforts to determine the
disability-adjusted years of life for myocarditis in this re-
gion should focus on improving diagnostic strategies.125
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Much of the world’s data on the demographics, presenting
symptoms, and natural history of histologically conﬁrmed
myocarditis comes from Western Europe. Multiple studies
from this region have demonstrated that viral genomes in
the heart are common in acute and chronic DCM and may
be associated with poor prognosis [49,50].
Of the 3,044 patients in the ESETCID (European
Study of Epidemiology and Treatment of Cardiac Inﬂam-
matory Diseases) trial with biopsy-conﬁrmed inﬂammatory
cardiomyopathy, 72% had dyspnea, 33% had chest pain,
and 18% had arrhythmic events [51]. A series of 174
patients with biopsy-proven myocarditis (active and
borderline) from Padua, Italy, had a similar distribution of
presenting symptoms (54% cardiomyopathy, 27% chest
pain, and 19% syncope or arrhythmia) [52]. In most series,
men were affected slightly more often and may have more
severe disease with a lower rate of LV functional recovery
than women. For example, in a cardiac MRI study of 65
patients with acute myocarditis, myocardial ﬁbrosis was
more frequent in men and in patients younger than 40
years [53].
The rate of myocarditis as a percent of DCM or sus-
pected myocarditis was described by several sources.
Eighty-four of 202 patients (41.6%) screened for a trial of
immunosuppressive therapy had myocarditis deﬁned by
increased HLA expression on EMB [54]. In a registry from
Germany, patients with suspected viral myocarditis had
myocarditis on EMB: 38% (69 of 181) using Dallas criteria
(hematoxylin and eosin stain) and 50% (91 of 181) when
immunoperoxidase criteria were used [55]. A total of 190
of 901 patients (21.1%) who underwent biopsy for
possible myocarditis in the TIMIC (Tailored Immunosup-
pression in Inﬂammatory Cardiomyopathy) trial had
myocarditis on EMB deﬁned by immunoperoxidase
criteria [56].
The likelihood of death or transplantation in acute and
chronic inﬂammatory cardiomyopathy varied somewhat
among reports. In the registry noted previously from
Padua, Italy, the risk of death or transplantation was 27%,
with an average follow-up duration of 23 months [52]. A
series of 203 patients from Germany with viral
genomeepositive cardiomyopathy (median follow-up of
4.7 years) revealed a 19.2% all-cause, 15% cardiac, and
9.9% sudden cardiac death rate [57]. Only 22% of the
patients (40 of 181) in another German registry followed
up for a mean of 59 months died or underwent heart
transplantation [55]. Among 84 patients from Poland with
more than 6 months of symptoms enrolled in a clinical
trial, the rate of death, heart transplantation, and hospital
readmission was 22.8% for the immunosuppression group
and 20.5% for the placebo (p ¼ nonsigniﬁcant) after 3
years (approximately 7% per year) [54]. In the TIMIC trial
from Rome, Italy, there were no deaths or transplantations
among 85 patients with biopsy-proven myocarditis at the
6-month study endpoint [56].The risk of chronic heart failure was also described in
Western European registries and trials of conﬁrmed
myocarditis. In the TIMIC trial, the natural history of in-
ﬂammatory cardiomyopathy was poor, with a decline in
average LV ejection fraction (LVEF) from 27.6% to 19.5%
over 6 months in the placebo arm [56]. In contrast, the
average LVEF improved from 23.8% to 30.2% over 6
months in the trial from Poland [54]. In patients with both
human herpesvirus 6 and parvovirus B19 infection, the
likelihood of ventricular functional recovery is low (LVEF
change 25% to 30% at follow-up) [49]. These studies
support the conclusion that adult patients with biopsy-
proven myocarditis (after 6 or more months of guideline-
based treatment) or multiple cardiac viral infections
rarely normalize cardiac function.
Western Europe has the infrastructure, including
experienced investigators, trialist networks, cardiac MRI
and EMB, and patient volumes, to conduct treatment trials
in myocarditis. Insights into the pathogenesis of viral and
autoimmune myocarditis in humans can arise from trans-
lational studies in these cohorts and large registries.
Adequate enrollment rates are likely given the 20% to 50%
regional rate of myocarditis in DCM.North America
The trials and registries from North America provided
invaluable data on the rate of LV recovery, death, and
transplantation in myocarditis. The demographics of acute
myocarditis were similar to those from European data
sources. For example, 62% of the 111 patients enrolled in the
US Myocarditis Treatment trial were male [58]. In a large
series from Johns Hopkins Hospital, the rate of myocarditis
as a percentage of patients with heart failure and suspected
myocarditis varied by year with a peak of 17% in 1986 [59].
At this medical center, 12% of 673 patients referred for
congestive heart failure due to DCM had myocarditis [60].
Distinct from many reports from Western Europe, viral
genome analysis and EMB in general were not as
commonly performed in North American studies of adult
patients with cardiomyopathy or chest pain syndromes.
Myocarditis case series from North America often relied on
a composite of clinical and imaging features to infer the
diagnosis of myocarditis [61].
Myocarditis is a common cause of DCM in children in
North America. Etiology was determined in the 1,426
children with DCM from the United States and Canada
enrolled in the Pediatric Cardiomyopathy Registry. Of the
485 patients (34%) with a known cause, the most common
cause was myocarditis (46% [222 of 485]). In this study,
half of myocarditis cases (52% [116 of 222]) met Dallas
histopathologic criteria. The risk of death or heart trans-
plantation was greater in DCM than in myocarditis [62].
The likelihood of LV recovery, death, and heart
transplantation in children with new-onset DCM due to
myocarditis was also described from the PediatricGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 121-129
FIGURE 5. Proportion of prevalent heart failure in the
2010 world population caused by myocarditis. HF, heart
failure.
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Cardiomyopathy Registry. Children with suspected
myocarditis were diagnosed with biopsy conﬁrmation (n ¼
119) or with probable myocarditis diagnosed clinically
(n ¼ 253) and were compared with children with idio-
pathic DCM (n ¼ 1,123). The median follow-up time for
survivors not undergoing heart transplantation was 3.1
years in the biopsy-conﬁrmed myocarditis group and 2.7
years in the probable myocarditis group. The distributions
of time to death, transplantation, and echocardiographic
normalization in the biopsy-conﬁrmed myocarditis and
probable myocarditis groups did not differ (Fig. 4). Chil-
dren with biopsy-conﬁrmed or probable myocarditis had
similar proportions of death, transplantation, and echo-
cardiographic normalization 3 years after presentation and
better outcomes than those of children with idiopathic
DCM [3]. The degree of LV functional recovery more than
6 months after diagnosis seemed greater than the LV re-
covery reported in adult case series.
In contrast to recent Western European studies in
which viral genome analysis was common, viral serology
or polymerase chain reaction was documented in only 94
patients. Of these, 31 (33%) had a positive ﬁnding (10
cytomegalovirus, 6 CVB, 5 enterovirus, 3 adenovirus, 2
Epstein-Barr virus, 2 herpes simplex virus, and 1 each of
hepatitis B virus, respiratory syncytial virus, and parvovirus).
The natural history of myocarditis in adults was
determined prospectively in 111 patients with biopsy-
proven myocarditis enrolled in the US Myocarditis Treat-
ment trial. In the group as a whole, LVEF improved from
25% at baseline to only 34% after 28 weeks. The mortality
rate for the entire group was 20% at 1 year and 56% at 4.3
years [58]. These data agree with those from the European
trial and registry ﬁndings that myocarditis presenting asFIGURE 4. Cumulative incidence rates of death, heart
transplantation, and left ventricular recovery in children
with myocarditis. Adapted with permission from Foerster
SR, Canter CE, Cinar A, et al. Ventricular remodeling and
survival are more favorable for myocarditis than for
idiopathic dilated cardiomyopathy in childhood: an out-
comes study from the Pediatric Cardiomyopathy Registry.
Circ Heart Fail 2010;3:689–97 [3].
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lihood of complete LV recovery.
Reported survival was similar in a large single-center
registry of biopsy-proven myocarditis from Massachusetts
General Hospital. Of 112 consecutive patients with histo-
pathologic conﬁrmation of myocarditis (55% lymphocytic),
88 (79%) and 63 (56%) were alive without cardiac trans-
plantation at 1 and 5 years [63]. In a series of patients with
biopsy-proven myocarditis from Johns Hopkins Hospital,
transplant-free survival of patients with fulminant myocar-
ditis (93% after 11 years) was signiﬁcantly better than that
for patients with acute myocarditis (45%; p ¼ 0.05 by the
log-rank test) [64]. For comparison, the outcomes of 373
patients with recent-onset DCM enrolled in a multicenter
North American registry revealed an increase in LVEF from
24% at entry to 40% at 6 months. Transplant-free survival
at 1, 2, and 4 years was 94%, 92%, and 88%, respectively;
survival free of heart failure hospitalization was 88%, 82%,
and 78% [65]. In this registry, biopsy was performed
infrequently, but histologically conﬁrmed myocarditis pre-
dicted bridge to recovery from LV device support [66].
The North American experience in myocarditis sug-
gested a composite rate of cardiomyopathy, trans-
plantation, and death of more than 50% after 5 years.
However, the impact of recent improvements in heart
failure care may not be reﬂected in these data. In addition,
the inﬂuence of inﬂammation on the outcome of more
chronic DCM has not been studied in this region. The
infrastructure for clinical investigation makes a randomized
trial to evaluate the effect of EMB on the outcome of sus-
pected myocarditis feasible.
SUMMARY
This review of the world’s literature on myocarditis iden-
tiﬁed gaps that hindered epidemiological analysis but also
permitted the identiﬁcation of strategies to address these
gaps in the 2013 GBD project. Speciﬁc causes of myocar-
ditis vary by world region and may require region-speciﬁc
screening and diagnostic strategies. Globally, the diagnostic127
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128tests for myocarditis, including EMB and MRI, are not
widely available, limiting the ability to identify myocarditis
in cross-sectional studies. Thus, the 2010 GBD report
probably underestimated the true rate of myocarditis as a
cause of heart failure (Fig. 5). Clinical trials to test diag-
nostic strategies and treatments in acute and chronic
myocarditis are currently feasible in Western Europe and
North America. In the next GBD project, the use of large
payor claims databases and standardized noninvasive
diagnostic criteria may allow for population-based esti-
mates for myocarditis separate from cardiomyopathy.REFERENCES
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